At times it is important to view past news in its proper perspective to understand where we are now.
Progress is being made; look at what has been achieved since this spring for a disease which we just became aware of this year. Below are highlighst of the PRs from 2/18/2020
BRILACIDIN:
Feb - proposed as Covid 19 treatment
- signs MTA
- shipped to RBL,George Mason
Mar - sent to 2 University Virology Labs
Apr - Covid 19 inhibition in Vero kidney cells is dose dependent
-screening of 11,552 drugs proves it is a leading Covid19
drug. MOA inhibition protease to prevent replication
May -PHRI to study immunomodulatory and antiviral effects
-VERO cells reduced the viral titer of Covid19 by 75 percent
after only 1 hour of preincubation prior to infection
-virucidal mechanism of action shown unique among
Covid 19 drugs
-PHRI...blocks ACE protein binding to inhibit viral entry
June -Grant application supported by RBL
-Pan viral testing proposed for Encephalitis,MERs and SARS
-Human respiratory cells Covid19 reduced up to 97%
-non toxic in human cells
-6 million dollars raised by exercising warrants and
preferred shares
July -Phase 2 clinical trials planned and prioritized
-interactions with Health Authorities to obtain input and
guidance on trial design
-Steps begun with CDMO... for manufacture of drug
- UC drug formulation plans refined for clinical trial
- drafted a study protocol toward initiating a planned
for Covid 19 study
-Covid clinical trial planned for 4th quarter 2020
- 2 active arms in hospitalized patients
-drug level against Covid19 at levels less than ABSSI
Aug -peer review paper pre print to be released in Sept
-RBL studies to conclude
-inhibited SARS-CoV-2 when administered post-infection.
-Covid19 inhibited across its life cycle
-preventative treatment against Covid19 possible
-SI index among highest reported > 300
- effective at low concentrations
- William DeGrado Phd accepts role as Scientific Advisor
Sept {-Kevetrin articles shows good results in AML testing}
-Combined with Remdesivir lowers viral load by 99.85%
-Felt to be synergistic
-Primary effect is disrupting viral integrity and blocking
viral entry
-shown in a human intestinal epithelial cell line and in
primary fibroblast cells to inhibit Covid19
As you can see IPIX shareholders have received a whole series of good news over the last few months. IMO the next news will build on the foundation IPIX has built.
Of course no one can be certain of the outcomes of human clinical trials, but IPIX shareholders have all the reasons above to be optimistic.
JMO
GLTA Farrell
Progress is being made; look at what has been achieved since this spring for a disease which we just became aware of this year. Below are highlighst of the PRs from 2/18/2020
BRILACIDIN:
Feb - proposed as Covid 19 treatment
- signs MTA
- shipped to RBL,George Mason
Mar - sent to 2 University Virology Labs
Apr - Covid 19 inhibition in Vero kidney cells is dose dependent
-screening of 11,552 drugs proves it is a leading Covid19
drug. MOA inhibition protease to prevent replication
May -PHRI to study immunomodulatory and antiviral effects
-VERO cells reduced the viral titer of Covid19 by 75 percent
after only 1 hour of preincubation prior to infection
-virucidal mechanism of action shown unique among
Covid 19 drugs
-PHRI...blocks ACE protein binding to inhibit viral entry
June -Grant application supported by RBL
-Pan viral testing proposed for Encephalitis,MERs and SARS
-Human respiratory cells Covid19 reduced up to 97%
-non toxic in human cells
-6 million dollars raised by exercising warrants and
preferred shares
July -Phase 2 clinical trials planned and prioritized
-interactions with Health Authorities to obtain input and
guidance on trial design
-Steps begun with CDMO... for manufacture of drug
- UC drug formulation plans refined for clinical trial
- drafted a study protocol toward initiating a planned
for Covid 19 study
-Covid clinical trial planned for 4th quarter 2020
- 2 active arms in hospitalized patients
-drug level against Covid19 at levels less than ABSSI
Aug -peer review paper pre print to be released in Sept
-RBL studies to conclude
-inhibited SARS-CoV-2 when administered post-infection.
-Covid19 inhibited across its life cycle
-preventative treatment against Covid19 possible
-SI index among highest reported > 300
- effective at low concentrations
- William DeGrado Phd accepts role as Scientific Advisor
Sept {-Kevetrin articles shows good results in AML testing}
-Combined with Remdesivir lowers viral load by 99.85%
-Felt to be synergistic
-Primary effect is disrupting viral integrity and blocking
viral entry
-shown in a human intestinal epithelial cell line and in
primary fibroblast cells to inhibit Covid19
As you can see IPIX shareholders have received a whole series of good news over the last few months. IMO the next news will build on the foundation IPIX has built.
Of course no one can be certain of the outcomes of human clinical trials, but IPIX shareholders have all the reasons above to be optimistic.
JMO
GLTA Farrell
18
